A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5169-5182

  Stehn, Justine R ^a   Haass, Nikolas K ^b,c,f   Bonello, Teresa ^a   Desouza, Melissa ^a   Kottyan, Gregg ⁱ   Treutlein, Herbert ^g   Zeng, Jun ^g   Nascimento, Paula R B B ^c   Sequeira, Vanessa B ^a   Butler, Tanya L ^d   Allanson, Munif ^b   Fath, Thomas ^a   Hill, Timothy A ^e   McCluskey, Adam ^e   Schevzov, Galina ^a   Palmer, Stephen J ^a   Hardeman, Edna C ^a   Winlaw, David ^d   Reeve, Vivienne E ^b   Dixon, Ian ^h   Weninger, Wolfgang ^b,c   Cripe, Timothy P ⁱ   Gunning, Peter W ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CENTENARY INSTITUTE   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h Genscreen Pty Ltd   (Australia)

ⁱ UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TROPOMYOSIN; ANTINEOPLASTIC AGENT; TR 100; TROPOMYOSIN; TROPOMYOSIN 2; TROPOMYOSIN 3; TROPOMYOSIN 6; TROPONIN I; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DISRUPTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; EMBRYO; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FUNCTION TEST; LONG TERM EXPOSURE; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; TUMOR SPHEROID;

EID: 84882680799     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4501     Document Type: Article

References (54)

1. Helfman DM, Flynn P, Khan P, Saeed A. Tropomyosin as a regulator of cancer cell transformation. Adv Exp Med Biol 2008;644:124-31.
2. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev 2009;28:5-14.
3. Rao J, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 2004;4:345-54.
4. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007; 1773:642-52.
5. Bonello TT, Stehn JR, Gunning PW. New approaches to targeting the actin cytoskeleton for chemotherapy. Future Med Chem 2009;1: 1311-31.
6. Bousquet PF, Paulsen LA, Fondy C, Lipski KM, Loucy KJ, Fondy TP. Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma. Cancer Res 1990;50: 1431-9.
7. Senderowicz AM, Kaur G, Sainz E, Laing C, Inman WD, Rodriguez J, et al. Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J Natl Cancer Inst 1995;87:46-51.
8. Newman DJ, Cragg GM. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 2004; 67:1216-38.
9. Gunning P, O'Neill G, Hardeman E. Tropomyosin-based regulation of the actin cytoskeleton in time and space. Physiol Rev 2008;88:1-35.
10. Li XE, Holmes KC, Lehman W, Jung H, Fischer S. The shape and flexibility of tropomyosin coiled coils: implications for Aatin filament assembly and regulation. J Mol Biol 2009;395:327-39.
11. Gunning PW, Schevzov G, Kee AJ, Hardeman EC. Tropomyosin isoforms: divining rods for actin cytoskeleton function. Trends Cell Biol 2005;15:333-41.
12. Bryce NS, Schevzov G, Ferguson V, Percival JM, Lin JJ, Matsumura F, et al. Specification of actin filament function and molecular composition by tropomyosin isoforms. Mol Biol Cell 2003;14:1002-16.
13. Tojkander S, Gateva G, Schevzov G, Hotulainen P, Naumanen P, Martin C, et al. A molecular pathway for myosin II recruitment to stress fibers. Curr Biol 2011;21:539-50.
14. Coulton AT, East DA, Galinska-Rakoczy A, Lehman W, Mulvihill DP. The recruitment of acetylated and unacetylated tropomyosin to distinct actin polymers permits the discrete regulation of specificmyosins in fission yeast. J Cell Sci 2010;123:3235-43.
15. Clayton JE, Sammons MR, Stark BC, Hodges AR, Lord M. Differential regulation of unconventional fission yeast myosins via the actin track. Curr Biol 2010;20:1423-31.
16. Stehn JR, Schevzov G, O'Neill GM, Gunning PW. Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy. Curr Cancer Drug Tar 2006;6:245-56.
17. Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O'Neill GM, et al. Tissue-specific tropomyosin isoform composition. J Histochem Cytochem 2005;53:557-70.
18. Gordon-Thomson C, Jones J, Mason RS, Moore GP. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 2005;15:21-8.
19. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol 2005;166:1541-54.
20. Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, et al. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho- ERK levels. Br J Cancer 2007;96:445-9.
21. Creed SJ, Bryce N, Naumanen P, Weinberger R, Lappalainen P, Stehn J, et al. Tropomyosin isoforms define distinct microfilament populations with different drug susceptibility. Euro J Cell Biol 2008;87: 709-20.
22. Bach CT, Creed S, Zhong J, Mahmassani M, Schevzov G, Stehn J, et al. Tropomyosin isoform expression regulates the transition of adhesions to determine cell speed and direction. Mol Cell Biol 2009; 29:1506-14.
23. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356-63.
24. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-44.
25. Smalley KS, Lioni M, Noma K, Haass NK, Herlyn M. In vitro 3D tumor microenvironment models for anti-cancer drug discovery. Expert Opin Drug Discov 2008;3:1-10.
26. Fath T, Ke YD, Gunning P, Gotz J, Ittner LM. Primary support cultures of hippocampal and substantia nigra neurons. Nat Protoc 2009;4:78-85.
27. Butler TL, Egan JR, Graf FG, Au CG, McMahon AC, North KN, et al. Dysfunction induced by ischemia versus edema: does edema matter? J Thorac Cardiovasc Surg 2009;138:141-7.
28. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
29. Thiele CJ. Neuroblastoma cell lines. In: Masters J editor. Human Cell Culture. Lancaster, UK: Kluwer Academic Publishers; 1998, p. 21-53
30. Kostyukova A, Hitchcock-DeGregori SE. Effect of structure of the N terminus of tropomyosin on tropomodulin function. J Biol Chem 2004;279:5066-71.
31. Watts KR, Morinaka BI, Amagata T, Robinson SJ, Tenney K, Bray WM, et al. Biostructural features of additional jasplakinolide (jaspamide) analogues. J Nat Prod 2011;74:341-51.
32. Ren J. Attenuated cardiac contractile responsiveness to insulin-like growth factor I in ventricular myocytes from biobreeding spontaneous diabetic rats. Cardiovasc Res 2000;46:162-71.
33. Schevzov G, Bryce NS, Almonte-Baldonado R, Joya J, Lin JJ, Hardeman E, et al. Specific features of neuronal size and shape are regulated by tropomyosin isoforms. Mol Biol Cell 2005;16: 3425-37.
34. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, et al. The mitogen-activated protein/extracellular signal- regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008;14:230-9.
35. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6.
36. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010;23:820-7.
37. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008;68:650-6.
38. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
39. Herraez E, Macias RI, Vazquez-Tato J, Hierro C, Monte MJ, Marin JJ. Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicol Appl Pharmacol 2009;239:21-8.
40. WolskaBM,WieczorekDM.The role of tropomyosin in the regulation of myocardial contraction and relaxation. Pflugers Archiv 2003; 446:1-8.
41. O'Neill GM, Stehn JR, Gunning PW. Tropomyosins as interpreters of the signalling environment to regulate the local cytoskeleton. Semin Cancer Biol 2007;18:35-44.
42. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001;11:41-7.
43. Blanchard EM, Iizuka K, Christe M, Conner DA, Geisterfer-Lowrance A, Schoen FJ, et al. Targeted ablation of the murine alpha-tropomyosin gene. Circ Res 1997;81:1005-10.
44. Jagatheesan G, Rajan S, Wieczorek DF. Investigations into tropomyosin function using mouse models. J Mol Cell Cardiol 2010;48:893-8.
45. Hook J, Lemckert F, Qin H, Schevzov G, Gunning P. Gamma tropomyosin gene products are required for embryonic development. Mol Cell Biol 2004;24:2318-23.
46. McMichael BK, Kotadiya P, Singh T, Holliday LS, Lee BS. Tropomyosin isoforms localize to distinct microfilament populations in osteoclasts. Bone 2006;39:694-705.
47. Wawro B, Greenfield NJ, Wear MA, Cooper JA, Higgs HN, Hitchcock- DeGregori SE. Tropomyosin regulates elongation by formin at the fast-growing end of the actin filament. Biochemistry 2007;46: 8146-55.
48. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997;278:294-8.
49. Odaka C, Sanders ML, Crews P. Jasplakinolide induces apoptosis in various transformed cell lines by a caspase-3-like protease- dependent pathway. Clin Diagn Lab Immunol 2000;7: 947-52.
50. Franklin-Tong VE, Gourlay CW. A role for actin in regulating apoptosis/ programmed cell death: evidence spanning yeast, plants and animals. Biochem J 2008;413:389-404.
51. Schevzov G, Fath T, Vrhovski B, Vlahovich N, Rajan S, Hook J, et al. Divergent regulation of the sarcomere and the cytoskeleton. J Biol Chem 2008;283:275-83.
52. Creed SJ, Desouza M, Bamburg JR, Gunning P, Stehn J. Tropomyosin isoform 3 promotes the formation of filopodia by regulating the recruitment of actin-binding proteins to actin filaments. Exp Cell Res 2010; 317:249-61.
53. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001;293:1829-32.
54. HookJ, Lemckert F, Schevzov G, Fath T, Gunning P. Functional identity of the gamma tropomyosin gene: implications for embryonic development, reproduction and cell viability. Bioarchitecture 2011;1:49-59.